SPDR S&P Pharmaceuticals ETF
XPH
XPH
65 hedge funds and large institutions have $110M invested in SPDR S&P Pharmaceuticals ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $932K
Holders
65
Holding in Top 10
–
Calls
$2K
Puts
$932K
Top Buyers
| 1 | +$13.3M | |
| 2 | +$4.4M | |
| 3 | +$3.37M | |
| 4 |
CI
CX Institutional
Auburn,
Indiana
|
+$3.16M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.28M |
Top Sellers
| 1 | -$4.71M | |
| 2 | -$4.29M | |
| 3 | -$4.13M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.46M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.34M |